Your browser doesn't support javascript.
loading
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Leleu, Xavier; Lee, Hans C; Zonder, Jeffrey A; Macro, Margaret; Ramasamy, Karthik; Hulin, Cyrille; Silar, Jiri; Kuhn, Matyas; Ren, Kaili; Bent-Ennakhil, Nawal; Cherepanov, Dasha; Stull, Dawn Marie; Terpos, Evangelos.
Afiliación
  • Leleu X; Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, 86000, France.
  • Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA.
  • Zonder JA; Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI 48201, USA.
  • Macro M; CHU de Caen, Caen, 14000, France.
  • Ramasamy K; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, OX3 7LE, UK.
  • Hulin C; CHU de Bordeaux, Bordeaux, 33000, France.
  • Silar J; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic.
  • Kuhn M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic.
  • Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA.
  • Bent-Ennakhil N; Takeda Pharmaceuticals International AG, Opfikon, 8152, Switzerland.
  • Cherepanov D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA.
  • Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA.
  • Terpos E; Department of Clinical Therapeutics, National & Kapodistrian University of Athens, School of Medicine, Athens,115 27, Greece.
Future Oncol ; 20(14): 935-950, 2024 May.
Article en En | MEDLINE | ID: mdl-38197267
ABSTRACT

Aim:

We pooled data from three observational studies (INSIGHT MM, UVEA-IXA and REMIX) to investigate the real-world effectiveness of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory myeloma. Materials &

methods:

INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. Patients who had received IRd as ≥2nd line of therapy were analyzed. Primary outcomes were time-to-next treatment (TTNT) and progression-free survival (PFS).

Results:

Overall, 564 patients were included (median follow-up 18.5 months). Median TTNT and PFS were 18.4 and 19.9 months; both outcomes were numerically longer for earlier versus later lines. Median treatment duration was 14.0 months. Overall response rate was 64.6%. No new safety concerns were noted.

Conclusion:

The effectiveness of IRd in routine practice appears similar to the efficacy observed in TOURMALINE-MM1. IRd benefit in earlier versus later lines was consistent with previous reports.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicina / Mieloma Múltiple Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Future Oncol Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glicina / Mieloma Múltiple Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Future Oncol Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido